Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Genome Sequencing of MRSA Infection Predicts Disease Severity

By Labmedica International staff writers
Posted on 24 Apr 2014
Image: The Genome Analyzer IIx (Photo courtesy of Illumina).
Image: The Genome Analyzer IIx (Photo courtesy of Illumina).
Image: The highly toxic methicillin-resistant Staphylococcus aureus (MRSA) strain (top) and less toxic strain (bottom) cultured on a blood agar plate (Photo courtesy of Ruth Massey).
Image: The highly toxic methicillin-resistant Staphylococcus aureus (MRSA) strain (top) and less toxic strain (bottom) cultured on a blood agar plate (Photo courtesy of Ruth Massey).
Bacterial pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), cause disease in part due to toxicity, or the bacterium's ability to damage a host's tissue.

The spread of the antibiotic-resistant pathogen remains a concerning public health problem, especially among doctors trying to determine appropriate treatment options for infected patients.

Microbiologists at the University of Bath (UK) and a team of international scientists used whole genome sequences from 90 MRSA isolates to identify over 100 genetic loci associated with toxicity. Bacterial adhesion to human fibronectin and fibrinogen was assessed and adherent bacteria were calculated by using the crystal violet method and absorbance measured at A595 using a microtiter plate reader. The toxicity of individual isolates was assayed in three ways.

The identification of genetic variation in the clinical isolates was studied using unique index-tagged libraries created for each sample, and up to 12 separate libraries were sequenced in each of eight channels in the Genome Analyzer GAIIx cells (Illumina; San Diego, CA, USA) with 75-base paired-end reads.

The authors found that by using whole genome sequences from 90 MRSA isolates they were able to identify over 100 genetic loci associated with toxicity and despite belonging to the same ST239 clone, the isolates varied greatly in toxicity. Importantly, the highly toxic isolates shared a common genetic signature. By looking for this signature in the MRSA genome, the investigators were able to predict which isolates were the most toxic and thus more likely to cause severe disease when used to infect mice.

Ruth C. Massey, PhD, the lead author of the study, said, “As the cost and speed of genome sequencing decreases, it is becoming increasingly feasible to sequence the genome of an infecting organism. In a clinical setting, sequencing may be useful for deciding the course of MRSA treatment. For example, a clinician may treat a highly toxic infection more aggressively, including prescribing certain antibiotics known to reduce toxin expression. The patient also may be monitored more closely for complications and isolated from others to help control the spread of infection.” The study was published on April 9, 2014, in the journal Genome Research.

Related Links:

University of Bath
Illumina



comments powered by Disqus

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.